Jpmorgan Chase & CO Rallybio Corp Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Rallybio Corp stock. As of the latest transaction made, Jpmorgan Chase & CO holds 944 shares of RLYB stock, worth $292. This represents 0.0% of its overall portfolio holdings.
Number of Shares
944
Previous 948
0.42%
Holding current value
$292
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding RLYB
# of Institutions
48Shares Held
32.4MCall Options Held
0Put Options Held
0-
Viking Global Investors LP4.19MShares$1.3 Million0.01% of portfolio
-
Johnson & Johnson New Brunswick, NJ3.64MShares$1.13 Million0.78% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA3.63MShares$1.13 Million1.63% of portfolio
-
New Leaf Venture Partners, L.L.C. New York, NY3.3MShares$1.02 Million4.83% of portfolio
-
Tpg Gp A, LLC Fort Worth, TX3.03MShares$938,8080.06% of portfolio
About Rallybio Corp
- Ticker RLYB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 32,132,000
- Market Cap $9.96M
- Description
- Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of feta...